| Fehm, Tanja |
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients |
|
|
| Recruiting | 4 | 1000 | Europe | Ribociclib | Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals | Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer | 10/24 | 10/26 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
|
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 43 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 06/24 | 12/25 | | |
|
| Recruiting | 3 | 1260 | Europe | Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios | West German Study Group, Eli Lilly and Company, Genomic Health®, Inc. | Breast Cancer Female | 08/26 | 03/28 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC |
|
|
| Active, not recruiting | 3 | 1684 | Europe | Ribociclib 200Mg Oral Tablet, Kisqali | West German Study Group, Novartis, Genomic Health®, Inc. | Breast Cancer Female | 07/27 | 07/27 | | |
| Recruiting | 3 | 1826 | Europe | preoperative radiotherapy, postoperative radiotherapy | Prof. Dr. Christiane Matuschek | Breast Cancer | 03/28 | 03/34 | | |
| Active, not recruiting | 2 | 136 | Europe | Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine | AGO Research GmbH, ImmunoGen, Inc. | Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma | 12/25 | 12/26 | | |
COMPRENDO, NCT05033756: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency ( |
|
|
| Active, not recruiting | 2 | 11 | Europe | Pembrolizumab Injection [Keytruda], Keytruda, Olaparib Oral Tablet [Lynparza], Lynparza | Institut fuer Frauengesundheit, Merck Sharp & Dohme LLC | Malignant Neoplasm of Breast, Breast Cancer | 01/25 | 02/26 | | |
DETECT-IVa, NCT02035813: DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). |
|
|
| Completed | 2 | 116 | Europe | Ribociclib, Kisqali, Eribulin, Halaven | Prof. Wolfgang Janni | HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female Patients | 01/24 | 01/24 | | |
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain |
|
|
| Active, not recruiting | 2 | 380 | Europe, US, RoW | OG-6219, Placebo | Organon and Co, Iqvia Pty Ltd | Endometriosis | 05/25 | 05/25 | | |
| Active, not recruiting | 2 | 180 | Europe | OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475 | ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC | Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 68 | Europe, US, RoW | Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio | Stemline Therapeutics, Inc., Stemline Therapeutics, Inc | Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases | 12/25 | 12/25 | | |
| Recruiting | N/A | 756 | Europe | Laparoscopic or robot-assisted radical/simple hysterectomy, Abdominal radical/simple hysterectomy | Hannover Medical School, German Cancer Aid | Cervical Cancer | 07/33 | 01/34 | | |
| Active, not recruiting | N/A | 989 | Europe, Canada, Japan, RoW | SLN biopsy only, SLN biopsy + PLN dissection | Centre Hospitalier Universitaire de Besancon, ARCAGY/ GINECO GROUP, European Network of Gynaecological Oncological Trial Groups (ENGOT) | Cervical Cancer | 05/27 | 05/29 | | |
| Wimberger, Pauline |
NeoON, NCT05036005: Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label |
|
|
| Recruiting | 4 | 108 | Europe | Ontruzant, SB3, Chemotherapy, Pertuzumab | Institut fuer Frauengesundheit, Samsung Bioepis Co., Ltd. | Breast Cancer, Breast Neoplasms, Breast Cancer Female, HER2-positive Breast Cancer | 04/23 | 07/23 | | |
COMPASS, NCT03164980: Comparison of QoL Between Trabectedin/PLD and Standard Platinum-based Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer |
|
|
| Completed | 4 | 89 | Europe | Trabectidin (Yondelis) | North Eastern German Society of Gynaecological Oncology, Frankfurter Institut für Klinische Krebsforschung IKF GmbH, PharmaMar | Quality of Life, Ovarian Cancer, Recurrent Ovarian Carcinoma | 08/23 | 08/23 | | |
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients |
|
|
| Recruiting | 4 | 1000 | Europe | Ribociclib | Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals | Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer | 10/24 | 10/26 | | |
MAMOC, NCT04227522: Rucaparib MAintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients |
|
|
| Completed | 3 | 42 | Europe | Rucaparib, Placebos | North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, Clovis Oncology, Inc. | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Clear Cell Carcinoma | 12/23 | 07/24 | | |
| Recruiting | 3 | 220 | Europe, Canada, US, RoW | Selinexor, KPT-330, Matching Placebo for selinexor | Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group | Endometrial Cancer | 01/25 | 01/28 | | |
|
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
|
|
| Recruiting | 3 | 500 | Europe, Canada, US, RoW | Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib | Sermonix Pharmaceuticals Inc. | Metastatic Breast Cancer | 04/27 | 04/28 | | |
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC |
|
|
| Active, not recruiting | 3 | 1684 | Europe | Ribociclib 200Mg Oral Tablet, Kisqali | West German Study Group, Novartis, Genomic Health®, Inc. | Breast Cancer Female | 07/27 | 07/27 | | |
| Active, not recruiting | 2 | 58 | Europe | Pazopanib plus Gemcitabine, Votrient and Gemzar, Pazopanib, Votrient | North Eastern German Society of Gynaecological Oncology, Novartis Pharmaceuticals, medac GmbH | Leiomyosarcoma or Carcinosarcoma | 12/24 | 12/24 | | |
| Active, not recruiting | 2 | 136 | Europe | Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine | AGO Research GmbH, ImmunoGen, Inc. | Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma | 12/25 | 12/26 | | |
| Terminated | 2 | 83 | Europe | Niraparib, Zejula | Mario Negri Institute for Pharmacological Research, North Eastern German Society of Gynaecological Oncology | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma | 08/24 | 08/24 | | |
NCT06433219: Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) |
|
|
| Recruiting | 2 | 60 | Europe, US, RoW | Tuvusertib (M1774), M1774, VXc-400, VRT-1363004, substance code MSC2584415A, Niraparib, GSK3985771, MK-4827, Lartesertib (M4076), M4076, substance code MSC2585823A | EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany | Ovarian Cancer | 01/28 | 01/28 | | |
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain |
|
|
| Active, not recruiting | 2 | 380 | Europe, US, RoW | OG-6219, Placebo | Organon and Co, Iqvia Pty Ltd | Endometriosis | 05/25 | 05/25 | | |
| Active, not recruiting | 2 | 180 | Europe | OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475 | ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC | Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | 12/25 | 12/25 | | |
N-Plus, NCT05460000: A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy |
|
|
| Recruiting | 2 | 640 | Europe | 3 cycles chemotherapy instead of 6 cycles chemotherapy, 6 cycles chemotherapy | North Eastern German Society of Gynaecological Oncology, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Clear Cell Carcinoma | 05/27 | 05/32 | | |
| Recruiting | 2 | 60 | Europe | olaparib, Lynparza, durvalumab, Imfinzi | AGO Research GmbH, AstraZeneca GmbH | Epithelial Ovarian Cancer | 01/28 | 06/28 | | |
| Recruiting | 2 | 240 | Europe | Atezolizumab 1200 mg in 20 ML Injection, Tecentriq, Inavolisib, Ipatasertib, Olaparib, Lynparza, Sacituzumab govitecan, Trodelvy, Trastuzumab/pertuzumab, Phesgo | German Cancer Research Center | Early-stage Breast Cancer | 03/30 | 12/30 | | |
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer |
|
|
| Recruiting | 1/2 | 400 | Europe, US, RoW | Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio | Stemline Therapeutics, Inc. | Breast Cancer, Metastatic Breast Cancer | 12/24 | 08/26 | | |
| Recruiting | N/A | 185 | Europe | combined exercise and nutrition intervention | Universitätsklinikum Hamburg-Eppendorf, Charite University, Berlin, Germany, University Hospital Dresden, Kliniken Essen-Mitte, University Hospital Tuebingen, University Hospital Schleswig-Holstein, Technical University of Munich | Ovarian Cancer, Malnutrition, Muscle Wasting, Fatigue | 07/25 | 12/25 | | |
| Active, not recruiting | N/A | 989 | Europe, Canada, Japan, RoW | SLN biopsy only, SLN biopsy + PLN dissection | Centre Hospitalier Universitaire de Besancon, ARCAGY/ GINECO GROUP, European Network of Gynaecological Oncological Trial Groups (ENGOT) | Cervical Cancer | 05/27 | 05/29 | | |
| Recruiting | N/A | 640 | Europe, Japan, RoW | Standard surgical procedure for endometrial cancer, systematic lymphadenectomy (LNE) | Philipps University Marburg, German Cancer Aid | Cancer of Endometrium Stage I, Cancer of Endometrium Stage II | 02/28 | 02/29 | | |
| Recruiting | N/A | 2000 | Europe | Genomic Profiling / Sequencing | German Cancer Research Center, University Hospital Heidelberg, German Federal Ministry of Education and Research | Early-Stage Breast Cancer, Neoadjuvant Therapy | 12/28 | 12/28 | | |
CATCH, NCT05652569: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer |
|
|
| Recruiting | N/A | 5000 | Europe | Genomic Profiling / Sequencing | German Cancer Research Center, University Hospital Heidelberg | Metastatic Breast Cancer | 12/30 | 12/30 | | |
| Korn, Sandra |
| Recruiting | N/A | 125 | Europe | IMPEDE, IMPEDE-FX or IMPEDE-FX RapidFill | Shape Memory Medical, Inc. | Peripheral Vascular Embolization | | | | |
OTW, NCT05386342: A PMCF Study Confirm the Performance and Safety of the TufTex Over-the-Wire () Embolectomy Catheters |
|
|
| Recruiting | N/A | 112 | Europe | TufTex Over-the-Wire Embolectomy Catheter | LeMaitre Vascular, Avania | Thrombus, Embolus, Occlusion; Vessel | 06/27 | 06/27 | | |
